for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

HUTCHMED (China) Ltd

0013.HK

Latest Trade

60.10HKD

Change

0.40(+0.67%)

Volume

449,000

Today's Range

58.60

 - 

60.60

52 Week Range

51.20

 - 

85.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
59.70
Open
59.70
Volume
449,000
3M AVG Volume
6.19
Today's High
60.60
Today's Low
58.60
52 Week High
85.80
52 Week Low
51.20
Shares Out (MIL)
864.37
Market Cap (MIL)
4,701.53
Forward P/E
-32.40
Dividend (Yield %)
--

Next Event

HUTCHMED (China) Ltd at Cantor Fitzgerald Global Healthcare 2021 Conference (Virtual)

Latest Developments

More

Hutchmed (China) Says NMPA Granted Breakthrough Therapy Designation To Amdizalisib

Hutchmed (China) Says Co And Astrazeneca Initiate Phase II Trial Of Orpathys

Capital Group Companies Inc's Long Position In HUTCHMED Rises To 9.15% - HKEX Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About HUTCHMED (China) Ltd

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Industry

Biotechnology & Drugs

Contact Info

22Nd Floor Hutchison House

10 Harcourt Road

00000

Hong Kong

+852.null.21281188

https://www.hutch-med.com/

Executive Leadership

Simon To

Executive Chairman of the Board

Christian Hogg

Chief Executive Officer, Executive Director

Chig Fung Cheng

Chief Financial Officer, Executive Director

Mark Lee

Senior Vice President - Corporate Finance & Development

May Wang

Senior Vice President - business development & strategic alliances

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.2K

2020

0.2K

2021(E)

0.3K
EPS (USD)

2018

-0.113

2019

-0.160

2020

-0.180

2021(E)

-0.233
Price To Earnings (TTM)
--
Price To Sales (TTM)
23.27
Price To Book (MRQ)
6.46
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.73
LT Debt To Equity (MRQ)
0.60
Return on Investment (TTM)
-24.19
Return on Equity (TTM)
-18.53

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up